Date: 2011-04-28
Type of information: Licensing agreement
Compound: two molecules for pain indications
Company: Flamel Technologies (France) Undisclosed specialty pharmaceutical company
Therapeutic area: CNS diseases
Type agreement: Licensing
Action mechanism:
Disease: pain
Details: Flamel Technologies has entered into a license agreement with a leading specialty pharmaceutical company for development and commercialization of two molecules for pain indications. The agreement is based on its Micropump® technology.
Financial terms: Pursuant to the agreement, Flamel will receive an upfront license fee of $3 million, as well as development-based milestones, and mid-single digit royalties upon eventual product sales.
Latest news: